A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS with IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)

Protocol No
BMS-CA0561060
Phase
III
Summary

This project is being done to learn more about Luspatercept if administrated at the maximum approved starting dose to assess that a quicker benefit can be seen in your transfusion burden and hemoglobin level.

Description
This project is being done to learn more about Luspatercept if administrated at the maximum approved starting dose to assess that a quicker benefit can be seen in your transfusion burden and hemoglobin level.

Participating Institutions
Froedtert Hospital
Status
SRC APPROVAL